A luminal unfolding microneedle injector for oral delivery of macromolecules.

Administration, Cutaneous Animals Drug Delivery Systems Equipment Design Humans Insulin / pharmacology Needles Swine

Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
10 2019
Historique:
received: 20 12 2018
accepted: 28 08 2019
pubmed: 9 10 2019
medline: 22 1 2020
entrez: 9 10 2019
Statut: ppublish

Résumé

Insulin and other injectable biologic drugs have transformed the treatment of patients suffering from diabetes

Identifiants

DOI: 10.1038/s41591-019-0598-9 PMID: 31591601 PMC: PMC7218658
pubmed: 31591601
doi: 10.1038/s41591-019-0598-9
pii: 10.1038/s41591-019-0598-9
pmc: PMC7218658
mid: NIHMS1565011
doi:

Substances chimiques

Insulin 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1512-1518

Subventions

Organisme : NCI NIH HHS
ID : R01 CA075289
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB000244
Pays : United States
Organisme : NIBIB NIH HHS
ID : R37 EB000244
Pays : United States
Organisme : Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
ID : R01-CA075289-21
Pays : International

Références

Turner, R. C., Cull, C. A., Frighi, V. & Holman, R. R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). J. Am. Med. Assoc. 281, 2005–2012 (1999).
doi: 10.1001/jama.281.21.2005
Pratley, R. E. et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375, 1447–1456 (2010).
doi: 10.1016/S0140-6736(10)60307-8
Korytkowski, M. When oral agents fail: practical barriers to starting insulin. Int. J. Obes. 26, S18–S24 (2002).
doi: 10.1038/sj.ijo.0802173
Boye, K. S. et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur. J. Heal. Econ. 12, 219–230 (2011).
doi: 10.1007/s10198-010-0224-8
Calvert, M. J., McManus, R. J. & Freemantle, N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br. J. Gen. Pract. 57, 455–460 (2007).
pubmed: 17550670 pmcid: 2078170
Cleland, J. & Langer, R. in Formulation and Delivery of Proteins and Peptides (eds. Cleland, J. L. & Langer, R.) 1–19 (American Chemical Society, 1994).
Dallel, N., Kacem, M., Nabouli, R. M. & El May, M. Disposal of insulin syringes by diabetic patients. Report of 100 patients.Tunis. Med. 83, 390–392 (2005).
pubmed: 16220694
Anselmo, A. C., Gokarn, Y. & Mitragotri, S. Non-invasive delivery strategies for biologics. Nat. Rev. Drug Discov. 18, 19–40 (2018).
doi: 10.1038/nrd.2018.183
Harrison, G. A. Insulin in alcoholic solution by the mouth. Br. Med. J. 2, 1204–1205 (1923).
doi: 10.1136/bmj.2.3286.1204
Abramson, A. et al. An ingestible self-orienting system for oral delivery of macromolecules. Science 363, 611–615 (2019).
doi: 10.1126/science.aau2277
Traverso, G. et al. Microneedles for drug delivery via the gastrointestinal tract. J. Pharm. Sci. 104, 362–367 (2015).
doi: 10.1002/jps.24182
Scudellari, M. Shot to the Gut: “Robotic” Pill Sails Through Human Safety Study. https://spectrum.ieee.org/the-human-os/biomedical/devices/shot-to-the-gut-robotic-pill-sails-through-human-safety-study (accessed 25 September 2019).
Vllasaliu, D., Thanou, M., Stolnik, S. & Fowler, R. Recent advances in oral delivery of biologics: nanomedicine and physical modes of delivery. Expert Opin. Drug Deliv. 15, 759–770 (2018).
doi: 10.1080/17425247.2018.1504017
Davies, M. et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes. J. Am. Med. Assoc. 318, 1460–1470 (2017).
doi: 10.1001/jama.2017.14752
Banerjee, A. et al. Ionic liquids for oral insulin delivery. Proc. Natl Acad. Sci. USA 115, 7296–7301 (2018).
doi: 10.1073/pnas.1722338115
Mathiowitz, E. et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386, 410–414 (1997).
doi: 10.1038/386410a0
Pridgen, E. M., Alexis, F. & Farokhzad, O. C. Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opin. Drug Deliv. 12, 1459–1473 (2015).
doi: 10.1517/17425247.2015.1018175
Banerjee, A., Wong, J., Gogoi, R., Brown, T. & Mitragotri, S. Intestinal micropatches for oral insulin delivery. J. Drug Target. 25, 608–615 (2017).
doi: 10.1080/1061186X.2017.1300664
Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655–672 (2014).
doi: 10.1038/nrd4363
Bass, D. M., Prevo, M. & Waxman, D. S. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS): a retrospective study. Drug Saf. 25, 1021–1033 (2002).
doi: 10.2165/00002018-200225140-00004
Coffey, J. W., Meliga, S. C., Corrie, S. R. & Kendall, M. A. F. Dynamic application of microprojection arrays to skin induces circulating protein extravasation for enhanced biomarker capture and detection. Biomaterials 84, 130–143 (2016).
doi: 10.1016/j.biomaterials.2016.01.015
Gatto, N. M. et al. Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J. Natl Cancer Inst. 95, 230–236 (2003).
doi: 10.1093/jnci/95.3.230
Podolsky, D. K. Healing the epithelium: solving the problem from two sides. J. Gastroenterol. 32, 122–126 (1997).
doi: 10.1007/BF01213309
Classen, M., Tytgat, G. & Lightdale, C. Gastroenterological Endoscopy (Thieme, 2010).
Velitchkov, N. G., Grigorov, G. I., Losanoff, J. E. & Kjossev, K. T. Ingested foreign bodies of the gastrointestinal tract: retrospective analysis of 542 cases. World J. Surg. 20, 1001–1005 (1996).
doi: 10.1007/s002689900152
Sandler, R. S., Stewart, W. F., Liberman, J. N., Ricci, J. A. & Zorich, N. L. Abdominal pain, bloating, and diarrhea in the United States. Dig. Dis. Sci. 45, 1166–1171 (2000).
doi: 10.1023/A:1005554103531
Bass, D. M., Prevo, M. & Waxman, D. S. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS: a retrospective study). Drug Saf. 25, 1021–1033 (2002).
doi: 10.2165/00002018-200225140-00004
Iddan, G., Meron, G., Glukhovsky, A. & Swain, P. Wireless capsule endoscopy. Nature 405, 417 (2000).
doi: 10.1038/35013140
Hellmig, S. et al. Gastric emptying time of fluids and solids in healthy subjects determined by
doi: 10.1111/j.1440-1746.2006.04449.x
Wang, Y. R., Fisher, R. S. & Parkman, H. P. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995–2004. Am. J. Gastroenterol. 103, 313–322 (2008).
doi: 10.1111/j.1572-0241.2007.01658.x
Snoeck, V. et al. Gastrointestinal transit time of nondisintegrating radio-opaque pellets in suckling and recently weaned piglets. J. Control. Release 94, 143–153 (2004).
doi: 10.1016/j.jconrel.2003.09.015
Cole, E. T. et al. Enteric coated HPMC capsules designed to achieve intestinal targeting. Int. J. Pharm. 231, 83–95 (2002).
doi: 10.1016/S0378-5173(01)00871-7
Ye, Y., Yu, J., Wen, D. & Kahkoska, A. R. Polymeric microneedles for transdermal protein delivery. Adv. Drug Deliv. Rev. 127, 106–118 (2018).
doi: 10.1016/j.addr.2018.01.015
Van Meer, L. et al. Injection site reactions after subcutaneous oligonucleotide therapy. Br. J. Clin. Pharmacol. 82, 340–351 (2016).
doi: 10.1111/bcp.12961
Fallingborg, J. Intraluminal pH of the human gastrointestinal tract. Dan. Med. Bull. 46, 183–196 (1999).
pubmed: 10421978

Auteurs

Alex Abramson (A)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
ORCID: 0000-0003-4876-9751

Ester Caffarel-Salvador (E)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
ORCID: 0000-0002-2844-7598

Vance Soares (V)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Daniel Minahan (D)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
ORCID: 0000-0003-3065-055X

Ryan Yu Tian (RY)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Xiaoya Lu (X)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

David Dellal (D)

David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.

Yuan Gao (Y)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Soyoung Kim (S)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Jacob Wainer (J)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Joy Collins (J)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Siddartha Tamang (S)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.

Alison Hayward (A)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA.

Tadayuki Yoshitake (T)

Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA, USA.

Hsiang-Chieh Lee (HC)

Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA, USA.

James Fujimoto (J)

Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA, USA.
ORCID: 0000-0002-0828-4357

Johannes Fels (J)

Global Research Technologies, Global Drug Discovery, Måløv, Denmark.
Device R&D, Novo Nordisk, Måløv, Denmark.
ORCID: 0000-0002-6616-6746

Morten Revsgaard Frederiksen (MR)

Global Research Technologies, Global Drug Discovery, Måløv, Denmark.
Device R&D, Novo Nordisk, Måløv, Denmark.
ORCID: 0000-0003-0000-4426

Ulrik Rahbek (U)

Global Research Technologies, Global Drug Discovery, Måløv, Denmark.
Device R&D, Novo Nordisk, Måløv, Denmark.

Niclas Roxhed (N)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Department of Micro and Nanosystems, KTH Royal Institute of Technology, Stockholm, Sweden.

Robert Langer (R)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. rlanger@mit.edu.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. rlanger@mit.edu.
Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA. rlanger@mit.edu.
Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. rlanger@mit.edu.
Media Lab, Massachusetts Institute of Technology, Cambridge, MA, USA. rlanger@mit.edu.
ORCID: 0000-0003-4255-0492

Giovanni Traverso (G)

Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. cgt20@mit.edu.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. cgt20@mit.edu.
Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. cgt20@mit.edu.
Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. cgt20@mit.edu.
ORCID: 0000-0001-7851-4077

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Voies d'administration de substances chimiques et des médicaments › Administration par voie topique › Administration par voie cutanée › A luminal unfolding microneedle injector for...
questionsmedicales.fr › Eucaryotes › Animaux › A luminal unfolding microneedle injector for...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › A luminal unfolding microneedle injector for...
questionsmedicales.fr › Techniques d'investigation › Conception d'appareillage › A luminal unfolding microneedle injector for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A luminal unfolding microneedle injector for...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Hormones peptidiques › Hormones pancréatiques › Insulines › Insuline › A luminal unfolding microneedle injector for...
questionsmedicales.fr › Équipement et fournitures › Aiguilles › A luminal unfolding microneedle injector for...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Artiodactyla › Suidae › A luminal unfolding microneedle injector for...